Acutaas Chemicals Limited (NSE:ACUTAAS)

Market Cap	197.37B +102.5%
Revenue (ttm)	12.15B +31.6%
Net Income	2.87B +136.4%
EPS	34.76 +159.1%
Shares Out	81.87M
PE Ratio	69.36
Forward PE	53.79
Dividend	1.50 (0.06%)
Ex-Dividend Date	n/a

Volume	246,696
Average Volume	633,518
Open	2,410.70
Previous Close	2,410.70
Day's Range	2,362.50 - 2,468.40
52-Week Range	1,040.50 - 2,634.80
Beta	-0.09
RSI	57.04
Earnings Date	May 30, 2026

About Acutaas Chemicals

Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 2004
• Employees: 879
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ACUTAAS

Financial Performance

In fiscal year 2025, Acutaas Chemicals's revenue was 10.07 billion, an increase of 40.34% compared to the previous year's 7.17 billion. Earnings were 1.59 billion, an increase of 271.06%.